Fibroblast Activation Markers and TGFBI in Therapy
AssigneeKeyBioscience AG
InventorsNicholas Willumsen, Cecilie Bager, Neel Nissen, Kim Henriksen, Morten Asser Karsdal
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for detecting markers of fibroblast activation in a patient by sandwich immunoassay to identify patients, particularly cancer patients who would benefit from anti-TGFβI therapy. The markers of fibroblast activation may be selected from the N-terminal pro-peptide of Collagen III (Pro-C3), the N-terminal pro-peptide of Collagen VI (Pro-C6), the N-terminal pro-peptide of Collagen I (Pro-C1) and/or an internal sequence in the N-terminal region of type 3 collagen (P3NP). The invention also provides an anti-TGFβI therapy for use in the treatment of cancer and/or fibrosis.
Claims26
A method for identifying a patient who is more likely to respond to anti-TGFβI therapy, said method using an immunoassay for detecting in a patient sample at least one marker of fibroblast activation, said method comprising:
- contacting said patient sample with a monoclonal antibody, wherein said monoclonal antibody is specifically reactive with an epitope of the marker of fibroblast activation;
- determining the amount of binding of said antibody;
- and
- correlating said amount of binding with values associated with normal healthy subjects, and/or with values associated with known responders to anti-TGFβI therapy, and/or with a predetermined cut-off value.
An agent which binds to the EMI domain of TGFβI or periostin or an analogue thereof.
26-28. (canceled)
Dependencies are inferred from the claim text.